The use of midazolam and haloperidol in cancer patients at the end of life

Singapore Medical Journal

Volumn 53, Issue 1, 2012, Pages 62-66

  Radha Krishna, L K ^a   Poulose, V J ^b   Goh, C ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Midazolam; Palliative care; Sedatives; Survival analysis; Terminal cancer

Indexed keywords

ADJUVANT; HALOPERIDOL; MIDAZOLAM; OPIATE;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CONFUSION; DRUG DOSE ESCALATION; DYSPNEA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NAUSEA; RESTLESSNESS; RETROSPECTIVE STUDY; REVIEW; TERMINAL CARE; TERMINALLY ILL PATIENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; FEMALE; HALOPERIDOL; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDAZOLAM; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; RETROSPECTIVE STUDIES; TERMINAL CARE; TERMINALLY ILL; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855854558     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Ventafridda V, Ripamonti C, De Conno F, Tamburini M, Cassileth BR. Symptom prevalence and control during cancer patients' last days of life. J Palliat Care 1990; 6:7-11.
2. Sykes N, Thorns A. Sedative use in the last week of life and the implications for end-of-life decision making. Arch Intern Med 2003; 163:341-4.
3. Fainsinger RL, Waller A, Bercovici M, et al. A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients. Palliat Med 2000; 14:257-65.
4. Fainsinger RL, De Moissac D, Mancini I, Oneschuk D. Sedation for delirium and other symptoms in terminally ill patients in Edmonton. J Palliat Care 2000; 16:5-10.
5. Stone P, Phillips C, Spruyt O, Waight C. A comparison of the use of sedatives in a hospital support team and in a hospice. Palliat Med 1997; 11:140-4.
6. Back IN. Terminal restlessness in patients with advanced malignant disease. Palliat Med 1992; 6:293-8.
7. Hardy J. Sedation in terminally ill patients. Lancet 2000; 356:1866-7.
8. Billings JA, Block SD. Slow euthanasia. J Palliat Care 1996; 12:21-30.
9. Morita T, Tsunoda J, Inoue S, Chihara S. Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manage 2001; 21:282-9.
10. Sykes N, Thorns A. The use of opioids and sedatives at the end of life. Lancet Oncol 2003; 4:312-8.
11. Claessens P, Menten J, Schotsmans P, Broeckaert B. Palliative sedation: a review of the research literature. J Pain Symptom Manage 2008; 36:310-33.
12. Burke AL, Diamond PL, Hulbert J, Yeatman J, Farr EA. Terminal restlessness--its management and the role of midazolam. Med J Aust 1991; 155:485-7.
13. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231-7.
14. Wilcock A, Twycross R, eds. Haloperidol in Drug Monographs Central Nervous System. Palliative Care Formulary 3rd ed (PCF 3). Oxfordshire: Palliativedrugs. com, 2007: 131-3.
15. Jackson KC, Lipman AG. Drug therapy for delirium in terminally ill patients. Cochrane Database Syst Rev, 2004; 2:CD004770.
16. Taylor D. Establishing a dose-response relationship for haloperidol decanoate (Abstract). Centre for Reviews and Dissemination. Database of Abstracts of Reviews of Effects Database of Abstracts of Reviews of Effects. In: National Institute for Health Research [online] 2010: 1. Available at: www.crd. york.ac.uk/crdweb/ShowRecord.asp?LinkFrom=OAI&ID=12005009685. Accessed Feburary 13, 2009.
17. Büttner M, Walder B, von Elm E, Tramèr MR. Is low-dose haloperidol a useful antiemetic: a meta-analysis of published and unpublished randomized trials. Anesthesiology 2004; 101:1451-63.
18. Cowan JD, Walsh D. Terminal sedation in palliative medicine: definition and review of the literature (Structured abstract). Centre for Reviews and Dissemination. Database of Abstracts of Reviews of Effects Database of Abstracts of Reviews of Effects. In: National Institute for Health Research [online] 2010: 1. Available at: www.crd.york.ac.uk/CRDWeb/ShowRecord. asp?ID=12001002278. Accessed Feburary 13, 2009.
19. Turner K, Chye R, Aggarwal G, et al. Dignity in dying: a preliminary study of patients in the last three days of life. J Palliat Care 1996; 12:7-13.
20. Morita T, Tsunoda J, Inoue S, Chihara S. Do hospice clinicians sedate patients intending to hasten death? J Palliat Care 1999; 15:20-3.
21. Good PD, Ravenscroft PJ, Cavenagh J. Effects of opioids and sedatives on survival in an Australian inpatient palliative care population. Intern Med J 2005; 35:512-7.
22. Chater S, Viola R, Paterson J, Jarvis V. Sedation for intractable distress in the dying--a survey of experts. Palliat Med 1998; 12:255-69.
23. Ramani S, Karnad AB. Long-term subcutaneous infusion of midazolam for refractory delirium in terminal breast cancer. South Med J 1996; 89:1101-3.
24. Gremaud G, Zulian GB. Indications and limitations of intravenous and subcutaneous midazolam in a palliative care center. J Pain Symptom Manage 1998; 15:331-3.
25. de Sousa E, Jepson BA. Midazolam in terminal care. Lancet 1988; 1:67-8.
26. Bottomley DM, Hanks GW. Subcutaneous midazolam infusion in palliative care. J Pain Symptom Manage 1990; 5:259-61.
27. Morita T, Tei Y, Inoue S. Correlation of the dose of midazolam for symptom control with administration periods: the possibility of tolerance. J Pain Symptom Manage 2003; 25:369-75.
28. Fainsinger RL, Landman W, Hoskings M, Bruera E. Sedation for uncontrolled symptoms in a South African hospice. J Pain Symptom Manage 1998; 16:145-52.
29. Shelly MP, Sultan MA, Bodenham A, Park GR. Midazolam infusions in critically ill patients. Eur J Anaesthesiol 1991; 8:21-7.